Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines
- PMID: 3366493
- DOI: 10.1002/ijc.2910410519
Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines
Abstract
The uptake system for 6-diazo-5-oxo-L-norleucine (DON) was studied in mouse P388 leukemia cells. The DON transport system was found to resemble that of another glutamine antimetabolite, Acivicin, in its strong temperature dependence, utilization of the "L" transport system, inhibition by glutamine but not by glutamate, potent inhibition by p-chloromercuribenzene sulfonate, Na+, and only minimal inhibition by various energy poisons. A Km of approximately 70 microM and a Vmax of 3.4 nmoles/10(6) cells/min was calculated for this cell line. The accumulated DON was not metabolized by P388 cells and moderate efflux occurred at 37 degrees C. The DON transport characteristics of a DON-resistant P388 cell line (100 times ID50 of parent line) were similar to those of the DON-sensitive parent line, indicating that altered drug transport may not be involved in development of resistance to this antimetabolite. The finding that an Acivicin-resistant subline of P388 cells which exhibited good transport of DON showed negligible transport of Acivicin suggests different modes of resistance towards the two glutamine antimetabolites.
Similar articles
-
Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.Cancer Res. 1981 Apr;41(4):1324-8. Cancer Res. 1981. PMID: 7214322
-
Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.Br J Cancer. 1987 Jun;55(6):653-6. doi: 10.1038/bjc.1987.133. Br J Cancer. 1987. PMID: 3620309 Free PMC article. No abstract available.
-
Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).Cancer Res. 1985 Jan;45(1):207-12. Cancer Res. 1985. PMID: 2578092
-
We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.Mol Cancer Ther. 2018 Sep;17(9):1824-1832. doi: 10.1158/1535-7163.MCT-17-1148. Mol Cancer Ther. 2018. PMID: 30181331 Free PMC article. Review.
-
Therapeutic resurgence of 6-diazo-5-oxo-l-norleucine (DON) through tissue-targeted prodrugs.Adv Pharmacol. 2024;100:157-180. doi: 10.1016/bs.apha.2024.04.003. Epub 2024 May 9. Adv Pharmacol. 2024. PMID: 39034051 Review.
Cited by
-
Relevance of glutamine metabolism to tumor cell growth.Mol Cell Biochem. 1992 Jul 6;113(1):1-15. doi: 10.1007/BF00230880. Mol Cell Biochem. 1992. PMID: 1640933 Review. No abstract available.
-
Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.Cancer Chemother Pharmacol. 1991;29(2):89-94. doi: 10.1007/BF00687316. Cancer Chemother Pharmacol. 1991. PMID: 1760863
-
Substrate-specificity of glutamine transporters in membrane vesicles from rat liver and skeletal muscle investigated using amino acid analogues.Biochem J. 1991 Aug 15;278 ( Pt 1)(Pt 1):105-11. doi: 10.1042/bj2780105. Biochem J. 1991. PMID: 1883322 Free PMC article.
-
Role of Stereochemistry on the Biological Activity of Nature-Inspired 3-Br-Acivicin Isomers and Derivatives.Molecules. 2023 Apr 3;28(7):3172. doi: 10.3390/molecules28073172. Molecules. 2023. PMID: 37049935 Free PMC article.
-
L-glutamine transport in native vesicles isolated from Ehrlich ascites tumor cell membranes.J Bioenerg Biomembr. 1991 Aug;23(4):689-97. doi: 10.1007/BF00785818. J Bioenerg Biomembr. 1991. PMID: 1917914
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources